Literature DB >> 9384476

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J W Sweetenham1, G Taghipour, D Milligan, A K Blystad, D Caballero, A Fassas, A H Goldstone.   

Abstract

The purpose of this study was to investigate the results of high-dose therapy and autologous stem cell transplantation in adult patients with Hodgkin's disease in first relapse after chemotherapy, to determine the overall and progression-free survival, identify prognostic factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose regimen. A retrospective analysis of 139 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between February 1984 and July 1995 is considered. Data on all patients were reviewed and prognostic factors determined in univariate analysis. The actuarial 5-year overall survival (OS) and progression-free survival (PFS) for the entire group of 139 patients were 49.4 and 44.7%, respectively. In univariate analysis for OS, disease bulk at the time of high-dose therapy, second-line regimen, initial remission duration and status at transplant had no predictive value. Status at transplant was predictive for OS when patients in second complete remission (CR) were analysed separately from those in chemosensitive relapse. Similar trends were observed for PFS. We concluded that high-dose therapy and autologous stem cell transplantation is an effective strategy for patients with Hodgkin's disease in first relapse after chemotherapy. These results suggest that it should be used regardless of initial remission duration. The role of conventional-dose salvage given prior to high-dose therapy is unclear, since disease status, disease bulk at the time of transplantation, and the second-line regimen had no significant effect on outcome. However, in view of the low patient numbers, no firm conclusion is possible, and this issue requires prospective assessment.

Entities:  

Mesh:

Year:  1997        PMID: 9384476     DOI: 10.1038/sj.bmt.1700963

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Kwonoh Park; Dok Hyun Yoon; Shin Kim; Chan-Sik Park; Jooryung Huh; Sang-Wook Lee; Cheolwon Suh
Journal:  Int J Hematol       Date:  2013-01-26       Impact factor: 2.490

2.  Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.

Authors:  Anna Colpo; Ephraim Hochberg; Yi-Bin Chen
Journal:  Oncologist       Date:  2011-12-30

3.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

4.  Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Anna Sureda; Carme Canals; Reyes Arranz; Dolores Caballero; Josep Maria Ribera; Mats Brune; Jacob Passweg; Rodrigo Martino; David Valcárcel; Joan Besalduch; Rafael Duarte; Angel León; Maria Jesus Pascual; Ana García-Noblejas; Lucia López Corral; Bianca Xicoy; Jordi Sierra; Norbert Schmitz
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

5.  High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.

Authors:  Craig H Moskowitz; Joachim Yahalom; Andrew D Zelenetz; Zhigang Zhang; Daniel Filippa; Julie Teruya-Feldstein; Tarun Kewalramani; Alison J Moskowitz; Robert David Rice; Jocelyn Maragulia; Jill Vanak; Tanya Trippett; Paul Hamlin; Steven Horowitz; Ariela Noy; Owen A O'Connor; Carol Portlock; David Straus; Stephen D Nimer
Journal:  Br J Haematol       Date:  2010-01-18       Impact factor: 6.998

6.  High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

Authors:  Ajay K Gopal; Tracee L Metcalfe; Ted A Gooley; John M Pagel; Stephen H Petersdorf; William I Bensinger; Leona Holmberg; David G Maloney; Oliver W Press
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 7.  Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

Authors:  Kevin A David; Lauren Mauro; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2007-10

8.  Assessing Prognostic Factors in Hodgkin's Lymphoma: Multistate Illness-Death Model.

Authors:  Fatemeh Javanmardi; Amal Saki-Malehi; Ahmad Ahmadzadeh; Fakher Rahim
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

Review 9.  New treatments for Hodgkin's disease.

Authors:  Jan-Peter Glossmann; Andreas Josting; Volker Diehl
Journal:  Curr Treat Options Oncol       Date:  2002-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.